Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer.

Brunet, M; Crombé, A; Cousin, S; Vanhersecke, L; Le Loarer, F; Bessede, A; Italiano, A

Brunet, M; Crombé, A; Cousin, S; Vanhersecke, L; Le Loarer, F; Bessede, A; Italiano, A.

Affiliation

Brunet M; Department of Medicine, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France.
Crombé A; Faculty of Medicine, University of Bordeaux, Bordeaux, France; Department of Radiology, CHU of Bordeaux, Bordeaux, France.
Cousin S; Department of Medicine, Institut Bergonié, Bordeaux, France.
Vanhersecke L; Faculty of Medicine, University of Bordeaux, Bordeaux, France; Department of Pathology, Institut Bergonié, Bordeaux, France.
Le Loarer F; Faculty of Medicine, University of Bordeaux, Bordeaux, France; Department of Pathology, Institut Bergonié, Bordeaux, France.
Bessede A; Explicyte, Bordeaux, France.
Italiano A; Department of Medicine, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France; Gustave Roussy, DITEP, Villejuif, France. Electronic address: a.italiano@bordeaux.unicancer.fr.

Ann Oncol ; 33(10): 1084-1085, 2022 10.

Article in En | MEDLINE | ID: mdl-35764273

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Tertiary Lymphoid Structures; Biomarkers; Carcinoma, Non-Small-Cell Lung/drug therapy; Humans; Immunotherapy; Lung Neoplasms/drug therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Tertiary Lymphoid Structures / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google